Lv594
1560 积分 2025-09-11 加入
路漫漫其修远兮，吾将上下而求索。
Early Combination Therapy vs Stepwise Escalation in Newly Diagnosed Type 2 Diabetes: A Systematic Review and Meta-analysis of Multiple Clinical Outcomes
5天前
已完结
IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes 2025
7天前
已完结
Type 2 diabetes as a disease of progressive loss of individual adipose storage capacity
8天前
已完结
Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular–kidney–metabolic stage progression: a real-world cohort study
15天前
已完结
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial
27天前
已完结
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial
27天前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
1个月前
已完结
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
1个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
1个月前
已完结
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050
1个月前
已完结
皖公网安备34019202002308
